<DOC>
	<DOC>NCT01149421</DOC>
	<brief_summary>The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).</brief_summary>
	<brief_title>A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<criteria>Type 2 diabetes taking 1 or more oral diabetes medications and have taken these medications for at least 1 month prior to screening Glycosylated hemoglobin (HbA1c) value ≥7% and ≤9.5% at screening Mean blood pressure &gt;90/60 millimeters of mercury (mmHg) and &lt;140/90 mmHg at screening If treated for hypertension, are taking 3 or less antihypertensive medications and have been taking these medications for at least 1 month prior to screening Stable weight for 3 months prior to screening Body mass index (BMI) greater than or equal to 23 kilogrammeter squared (kg/m^2) Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions Women of childbearing potential must test negative for pregnancy and be willing to use a reliable method of birth control Male participants must use a reliable method of birth control Myocardial infarction, stroke, or hospitalization for heart failure within 3 months prior to screening, or heart failure Class III or IV at screening Ongoing or history of frequent intermittent tachyarrhythmia Resting heart rate &lt;60 beats per minute (bpm) or &gt;100 bpm at screening Work rotating shifts or work during the hours of 2200 to 0700 Chronic insulin therapy Use of a glucagonlike peptide 1 (GLP1) receptor agonist within 3 months prior to screening, or a dipeptidylpeptidaseIV (DPPIV) inhibitor within 2 weeks prior to screening Nondominant arm circumference &gt;42 centimeter (cm) Use of drugs to promote weight loss Chronic use of systemic steroids Gastric emptying abnormality or bariatric surgery Hepatitis, other liver disease, or alanine transaminase (ALT) &gt;3 times the upper limit of normal Acute or chronic pancreatitis Severe renal impairment Active autoimmune disease or uncontrolled endocrine abnormality Self or family history of thyroid cancer, medullary Ccell hyperplasia, or type 2A or 2B multiple endocrine neoplasia Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at screening Transplanted organ except corneal transplants Active or untreated cancer or in remission &lt;5 years, except skin, in situ cervical, or prostate cancer Sicklecell disease, hemolytic anemia, or another hematological condition that may interfere with HbA1c testing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Ambulatory Blood Pressure Monitoring</keyword>
	<keyword>ABPM</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Heart Rate</keyword>
</DOC>